China Factory for Ibutamoren Mesylate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex
China Factory for Ibutamoren Mesylate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:
Product Detail
| Name | Desmopressin |
| CAS number | 16679-58-6 |
| Molecular formula | C46H64N14O12S2 |
| Molecular weight | 1069.22 |
| EINECS Number | 240-726-7 |
| Specific rotation | D25 +85.5 ± 2° (calculated for the free peptide) |
| Density | 1.56±0.1 g/cm3(Predicted) |
| RTECS No. | YW9000000 |
| Storage conditions | Store at 0°C |
| Solubility | H2O:soluble20mg/mL, clear, colorless |
| Acidity coefficient | (pKa) 9.90±0.15 (Predicted) |
Synonyms
MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN
Indications
(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.
(2) Treatment of nocturnal enuresis (patients aged 5 years or older).
(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.
(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.
Treatment of diabetes insipidus
Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.
Product detail pictures:
Related Product Guide:
With our leading technology at the same time as our spirit of innovation,mutual cooperation, benefits and growth, we're going to build a prosperous future together with your esteemed firm for China Factory for Ibutamoren Mesylate - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Ecuador, Afghanistan, Myanmar, We have a professional sales team, they have mastered the best technology and manufacturing processes, have years of experience in foreign trade sales, with customers able to communicate seamlessly and accurately understand the real needs of customers, providing customers with personalized service and unique products.
By Debby from Porto - 2018.06.19 10:42
The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
By Geraldine from Grenada - 2018.06.21 17:11
